- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: INNO-406 | Lyn-IN-1 | NS-187
Compound class: Synthetic organic
Comment: Bafetinib is a second-generation, dual Lyn/Abl kinase inhibitor [1,6] with therapeutic.potential for the treatment of imatinib-resistant or -intolerant B-cell chronic lymphocytic leukemia (CLL), and prostate cancer. Data indicate that bafetinib crosses the blood-brain-barrier, reaching therapeutic concentration, so the drug's potential for treatment of brain tumours is also under investigation.
Note that we have mapped the chemical structure using the updated CAS registry number stipulated in INN proposed list 101 (2009) to the CID specified here, but the name maps to four other CIDs in PubChem.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Bafetinib is included in GtoImmuPdb based on its potential clinical utility as a treatment for leukemia.|
|B-cell chronic lymphocytic leukemia||
|FDA and EMA orphan drug for Philadelphia chromosome-positive CML. Phase 2 clinical trial in B cell CLL has been completed (see NCT01144260).|